Claude helps discover novel CRISPR-like enzyme system in Anthropic's first wet-lab result

Anthropic framed this as a milestone: an AI model contributing directly to a biology discovery, produced through its newly opened wet lab. Claude analyzed large DNA databases and surfaced a molecular machine — Array-Associated Reverse Transcriptases — with features the company says were unrecognized in prior studies and reminiscent of CRISPR systems. Dario Amodei posted that the team suspects it could represent a new gene-editing mechanism, while explicitly cautioning that its precise function, biotechnological utility, and significance are not yet established.

Mechanically, the result came from computational pattern-finding across genetic databases rather than a lab-first screen, which is exactly the point of contention. It positions Claude as a hypothesis-generation engine for the life sciences, dovetailing with the Life Sciences Verification Program announced alongside Opus 5.5.

The community reaction was pointed. A Hacker News thread with 526 points and roughly 550 comments was skeptical: researchers stressed the function is still unknown and that 'CRISPR-like' overstates what is, for now, a computational pipeline rather than a deployable gene-editing tool. The broader dual-use debate — whether AI-accelerated biology discovery outruns safety oversight — is intensifying, especially given Anthropic's simultaneous loosening of bio guardrails for verified partners. What to watch: peer-reviewed validation and whether independent labs can confirm ART's activity in vitro.